@article{TLCR834,
author = {Alejandro Navarro Mendivil and Pablo Martinez Rodriguez and Enriqueta Felip},
title = {Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial},
journal = {Translational Lung Cancer Research},
volume = {2},
number = {1},
year = {2013},
keywords = {},
abstract = {Angiogenesis, the development and formation of new blood vessels, has been described as one of the hallmarks of cancer, playing an important role in tumor growth, invasion and metastasis (1-4). Several signaling pathways are implicated, such as the vascular endothelial growth factor (VEGF) pathway and platelet-derived growth factor (PDGF) pathway (5). Inhibiting tumor angiogenesis is a therapeutic strategy that has been tested in different solid tumors, including non-small cell lung cancer (NSCLC) (6-8).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/834}
}